Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
7 results
  • Metastatic/Advanced Cancer, Gallbladder and Bile Duct Cancers, Liver Cancer, Brain Tumors, Sarcoma

20-487          Phase I

A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 Mutations (View details on clinicaltrial.gov)

  • Uterine Cancer, Gallbladder and Bile Duct Cancers, Lung Cancer, Bladder Cancer, Breast Cancer, Cervical Cancer

21-043          Phase II

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (View details on clinicaltrial.gov)

  • Gallbladder and Bile Duct Cancers

19-502          Phase III

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: the PROOF Trial (View details on clinicaltrial.gov)

  • Gallbladder and Bile Duct Cancers

14-328          Phase II

A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy (View details on clinicaltrial.gov)

  • Gallbladder and Bile Duct Cancers, Liver Metastases

17-517          Phase II

A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer (View details on clinicaltrial.gov)

  • Gallbladder and Bile Duct Cancers, Liver Cancer

20-645          Phase III

An Open-Label Expanded Access Program of Futibatinib (TAS-120) In Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (View details on clinicaltrial.gov)

  • Lung Cancer, Gallbladder and Bile Duct Cancers, Head and Neck Cancer, Endometrial Cancer, Bladder Cancer

20-473          Phase II

Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) (View details on clinicaltrial.gov)

Showing 1 - 10 of 7 results